Literature DB >> 34366338

A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimer's Disease Based on Cogstate One Card Learning Accuracy Performance.

Shehroo B Pudumjee1, Emily S Lundt2, Sabrina M Albertson2, Mary M Machulda1, Walter K Kremers2, Clifford R Jack3, David S Knopman4, Ronald C Petersen5, Michelle M Mielke4,5, Nikki H Stricker1.   

Abstract

BACKGROUND: Longitudinal, but not cross-sectional, cognitive testing is one option proposed to define transitional cognitive decline for individuals on the Alzheimer's disease continuum.
OBJECTIVE: Compare diagnostic accuracy of cross-sectional subtle objective cognitive impairment (sOBJ) and longitudinal objective decline (ΔOBJ) over 30 months for identifying 1) cognitively unimpaired participants with preclinical Alzheimer's disease defined by elevated brain amyloid and tau (A+T+) and 2) incident mild cognitive impairment (MCI) based on Cogstate One Card Learning (OCL) accuracy performance.
METHODS: Mayo Clinic Study of Aging cognitively unimpaired participants aged 50 + with amyloid and tau PET scans (n = 311) comprised the biomarker-defined sample. A case-control sample of participants aged 65 + remaining cognitively unimpaired for at least 30 months included 64 who subsequently developed MCI (incident MCI cases) and 184 controls, risk-set matched by age, sex, education, and visit number. sOBJ was assessed by OCL z-scores. ΔOBJ was assessed using within subjects' standard deviation and annualized change from linear regression or linear mixed effects (LME) models. Concordance measures Area Under the ROC Curve (AUC) or C-statistic and odds ratios (OR) from conditional logistic regression models were derived. sOBJ and ΔOBJ were modeled jointly to compare methods.
RESULTS: sOBJ and ΔOBJ-LME methods differentiated A+T+ from A-T- (AUC = 0.64, 0.69) and controls from incident MCI (C-statistic = 0.59, 0.69) better than chance; other ΔOBJ methods did not. ΔOBJ-LME improved prediction of future MCI over baseline sOBJ (p = 0.003) but not over 30-month sOBJ (p = 0.09).
CONCLUSION: Longitudinal decline did not offer substantial benefit over cross-sectional assessment in detecting preclinical Alzheimer's disease or incident MCI.

Entities:  

Keywords:  Amyloid; biomarker; cognigram; memory; neuropsychology; reliable change index; sensitivity and specificity; tau; transitional cognitive decline; validity

Mesh:

Substances:

Year:  2021        PMID: 34366338      PMCID: PMC8506654          DOI: 10.3233/JAD-210251

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  60 in total

1.  Intraindividual cognitive decline using a brief computerized cognitive screening test.

Authors:  David G Darby; Robert H Pietrzak; Julia Fredrickson; Michael Woodward; Lynette Moore; Amy Fredrickson; Jack Sach; Paul Maruff
Journal:  Alzheimers Dement       Date:  2012       Impact factor: 21.566

2.  Neuropsychological subtypes of incident mild cognitive impairment in the Mayo Clinic Study of Aging.

Authors:  Mary M Machulda; Emily S Lundt; Sabrina M Albertson; Walter K Kremers; Michelle M Mielke; David S Knopman; Mark W Bondi; Ronald C Petersen
Journal:  Alzheimers Dement       Date:  2019-05-23       Impact factor: 21.566

3.  Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing.

Authors:  Christopher C Rowe; Pierrick Bourgeat; Kathryn A Ellis; Belinda Brown; Yen Ying Lim; Rachel Mulligan; Gareth Jones; Paul Maruff; Michael Woodward; Roger Price; Peter Robins; Henri Tochon-Danguy; Graeme O'Keefe; Kerryn E Pike; Paul Yates; Cassandra Szoeke; Olivier Salvado; S Lance Macaulay; Timothy O'Meara; Richard Head; Lynne Cobiac; Greg Savage; Ralph Martins; Colin L Masters; David Ames; Victor L Villemagne
Journal:  Ann Neurol       Date:  2013-12       Impact factor: 10.422

4.  Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects.

Authors:  David S Knopman; Emily S Lundt; Terry M Therneau; Prashanthi Vemuri; Val J Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Michelle M Mielke; Mary M Machulda; Bradley F Boeve; David T Jones; Jon Graff-Radford; Sabrina M Albertson; Christopher G Schwarz; Ronald C Petersen; Clifford R Jack
Journal:  Brain       Date:  2019-04-01       Impact factor: 13.501

5.  Episodic memory decline predicts cortical amyloid status in community-dwelling older adults.

Authors:  David G Darby; Amy Brodtmann; Robert H Pietrzak; Julia Fredrickson; Michael Woodward; Victor L Villemagne; Amy Fredrickson; Paul Maruff; Christopher Rowe
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

6.  The short test of mental status. Correlations with standardized psychometric testing.

Authors:  E Kokmen; G E Smith; R C Petersen; E Tangalos; R C Ivnik
Journal:  Arch Neurol       Date:  1991-07

7.  Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition.

Authors:  Prashanthi Vemuri; Val J Lowe; David S Knopman; Matthew L Senjem; Bradley J Kemp; Christopher G Schwarz; Scott A Przybelski; Mary M Machulda; Ronald C Petersen; Clifford R Jack
Journal:  Alzheimers Dement (Amst)       Date:  2016-12-21

8.  Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses.

Authors:  Daniel A Nation; Jean K Ho; Shubir Dutt; S Duke Han; Mark H C Lai
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

9.  Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration.

Authors:  Kelsey R Thomas; Katherine J Bangen; Alexandra J Weigand; Emily C Edmonds; Christina G Wong; Shanna Cooper; Lisa Delano-Wood; Mark W Bondi
Journal:  Neurology       Date:  2019-12-30       Impact factor: 11.800

10.  Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative.

Authors:  Anna H Noel-Storr; Jenny M McCleery; Edo Richard; Craig W Ritchie; Leon Flicker; Sarah J Cullum; Daniel Davis; Terence J Quinn; Chris Hyde; Anne W S Rutjes; Nadja Smailagic; Sue Marcus; Sandra Black; Kaj Blennow; Carol Brayne; Mario Fiorivanti; Julene K Johnson; Sascha Köpke; Lon S Schneider; Andrew Simmons; Niklas Mattsson; Henrik Zetterberg; Patrick M M Bossuyt; Gordon Wilcock; Rupert McShane
Journal:  Neurology       Date:  2014-06-18       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.